Thermo Fisher Scientific Inc TMO
Price alert —
Sign in to get a one-time email the moment TMO crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · TMO
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11.0B | $1.7B | $1.9B | $0.8B | 15.0% | 17.4% |
| 2025-12-31 | $12.2B | $2.0B | $2.3B | $3.0B | 16.1% | 18.9% |
| 2025-09-30 | $11.1B | $1.6B | $2.1B | $1.8B | 14.5% | 18.7% |
| 2025-06-30 | $10.9B | $1.6B | $1.9B | $1.1B | 14.9% | 17.7% |
| 2025-03-31 | $10.4B | $1.5B | $1.8B | $0.4B | 14.5% | 17.5% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare TMO vs peers
Line TMO up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with TMO
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-04-23 | 5.44 | 5.24 | +3.8% | +0.6% |
| 2026-01-29 | 6.57 | 6.45 | +1.9% | -2.3% |
| 2025-10-22 | 5.79 | 5.50 | +5.3% | +0.8% |
| 2025-07-23 | 5.36 | 5.23 | +2.5% | +1.8% |
| 2025-04-23 | 5.15 | 5.10 | +0.9% | -1.1% |
| 2025-01-30 | 6.10 | 5.94 | +2.7% | -1.5% |
| 2024-10-23 | 5.28 | 5.25 | +0.5% | -3.3% |
| 2024-07-24 | 5.37 | 5.13 | +4.7% | +3.4% |
| 2024-04-24 | 5.11 | 4.71 | +8.4% | -1.0% |
| 2024-01-31 | 5.67 | 5.65 | +0.4% | +2.5% |
| 2023-10-25 | 5.69 | 5.61 | +1.4% | +1.6% |
| 2023-07-26 | 5.15 | 5.43 | -5.2% | -2.5% |
| 2023-04-26 | 5.03 | 5.03 | -0.1% | +1.9% |
| 2023-02-01 | 5.40 | 5.20 | +3.8% | -0.1% |
| 2022-10-26 | 5.08 | 4.82 | +5.5% | -0.9% |
| 2022-07-28 | 5.51 | 4.98 | +10.6% | +0.1% |
| 2022-04-28 | 7.25 | 6.21 | +16.8% | -1.1% |
| 2022-02-02 | 6.54 | 5.27 | +24.0% | -1.5% |
| 2021-10-27 | 5.76 | 4.70 | +22.7% | +1.3% |
| 2021-07-28 | 5.60 | 5.47 | +2.3% | +1.0% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO ★ | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
| ABT | $175B | 28.2 | 16.6 | 3.8 | 17.1 | 3.4 | 56.8% | 13.0% | -47.5% | — |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 34.45%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 30,427,192 | 8.19% |
| Vanguard Capital Management LLC | 24,280,816 | 6.53% |
| State Street Corporation | 16,731,668 | 4.50% |
| Morgan Stanley | 10,863,528 | 2.92% |
| FMR, LLC | 10,776,436 | 2.90% |
| Geode Capital Management, LLC | 8,407,891 | 2.26% |
| Franklin Resources, Inc. | 6,813,031 | 1.83% |
| JPMORGAN CHASE & CO | 6,795,482 | 1.83% |
| Capital World Investors | 6,646,316 | 1.79% |
| Price (T.Rowe) Associates Inc | 6,315,471 | 1.70% |
Insider activity · 90d
10 buys / 1 sells · ratio 10.0 · Finnhub
- Keith R. Alexandra BUY 2,602
- WEISLER DION J BUY 5,446
- WEISLER DION J F 4,947 @ $451.79
- Spar Debora L BUY 2,610
- Jacks Tyler BUY 9,462
- CHANDY RUBY R BUY 3,463
- Lynch Karen S BUY 1,159
- Chai Nelson BUY 15,316
- HARRIS C MARTIN BUY 9,532
- SPERLING SCOTT M BUY 69,479
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-06-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-30 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-30 | PRIMARY DOCUMENT | view · |
| 8-K | 2026-05-26 | 8-K | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 10-Q | 2026-05-01 | 10-Q | view · |
| 4 | 2026-04-29 | PRIMARY DOCUMENT | view · |
| 8-K | 2026-04-23 | 8-K | view · |
| DEF 14A | 2026-04-07 | DEF 14A | view · |
| 4 | 2026-03-31 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-31 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-31 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-31 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-31 | PRIMARY DOCUMENT | view · |
| 8-K | 2026-03-24 | 8-K | view · |
| 4 | 2026-03-12 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-09 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-05 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-27 | PRIMARY DOCUMENT | view · |
| 10-K | 2026-02-26 | 10-K | view · |
| 8-K | 2026-02-12 | 8-K | view · |
| 4 | 2026-02-11 | PRIMARY DOCUMENT | view · |
| 8-K | 2026-01-29 | 8-K | view · |
| 8-K | 2026-01-12 | 8-K | view · |
| 4 | 2026-01-05 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-05 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-05 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-05 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-05 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-11 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-05 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-04 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-03 | PRIMARY DOCUMENT | view · |
About TMO
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbio…
Options picks · TMO
ITM + OTM ideas from the latest scanLoading…
Congress trades · TMO
STOCK Act disclosuresLoading…
SEC filings & insiders · TMO
EDGAR · liveLoading…
Holders · TMO
Institutions & insider activityLoading…